The safety and immunogenicity of an adenovirus type 35-vectored TB vaccine in HIV-infected, BCG-vaccinated adults with CD4+ T cell counts >350 cells/mm3

Vaccine

Volumn 33, Issue 15, 2015, Pages 1890-1896

  Churchyard, Gavin John ^a,b   Snowden, Margaret Ann ^c   Hokey, David ^c   Dheenadhayalan, Veerabadran ^c   McClain, J Bruce ^c   Douoguih, Macaya ^d   Pau, Maria Grazia ^d   Sadoff, Jerry ^d   Landry, Bernard ^c  

^a AURUM INSTITUTE   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c AERAS   (United States)

^d CRUCELL HOLLAND BV   (Netherlands)

Author keywords

Clinicaltrials.gov (NHREC no. NCT01017536); DOH 27 0809 2497; HIV; Immunogenicity; Safety; Tuberculosis; Vaccines

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BCG VACCINE; GAMMA INTERFERON; HEMOGLOBIN; INTERLEUKIN 2; MYCOBACTERIUM ANTIGEN; PLACEBO; TUMOR NECROSIS FACTOR; AERAS-402; BACTERIAL ANTIGEN; BACTERIUM ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRIDAE; ADENOVIRUS TYPE 35; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIBODY RESPONSE; ARTHRALGIA; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BCG VACCINATION; BRONCHITIS; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONJUNCTIVITIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIARRHEA; DOUBLE BLIND PROCEDURE; DYSPEPSIA; DYSURIA; ELEVATED BLOOD PRESSURE; EXTERNAL OTITIS; FATIGUE; FEMALE; FEVER; FOLLOW UP; GASTROENTERITIS; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNOGENICITY; INFLUENZA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; LYMPHADENOPATHY; MALE; MYALGIA; NEUTROPHIL COUNT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SIDE EFFECT; STOMATITIS; THRUSH; TUBERCULOSIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VAGINITIS; VIRUS LOAD; BLOOD; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; INTRAMUSCULAR DRUG ADMINISTRATION; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA; VACCINATION; YOUNG ADULT;

ADULT; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BCG VACCINE; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; INJECTIONS, INTRAMUSCULAR; INTERFERON-GAMMA; INTERLEUKIN-2; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; SOUTH AFRICA; TUBERCULOSIS; TUBERCULOSIS VACCINES; TUMOR NECROSIS FACTOR-ALPHA; VACCINATION; VIRAL LOAD; YOUNG ADULT;

EID: 84925234557     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.02.004     Document Type: Article

References (20)

1. World Health Organisation Global tuberculosis report 2013. WHO/HTM/TB/2013.11 2012, World Health Organisation, Geneva, Switzerland.
2. Barreto M.L., Pereira S.M., Pilger D., Cruz A.A., Cunha S.S., Sant'Anna C., et al. Evidence of an effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: second report of the BCG-REVAC cluster-randomised trial. Vaccine 2011, 29:4875-4877.
3. Rodrigues L.C., Pereira S.M., Cunha S.S., Genser B., Ichihara M.Y., de Brito S.C., et al. Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial. Lancet 2005, 366:1290-1295.
4. Hoft D.F., Blazevic A., Stanley J., Landry B., Sizemore D., Kpamegan E., et al. A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity. Vaccine 2012, 30:2098-2108.
5. + T cells in adults. Am J Respir Crit Care Med 2010, 181:1407-1417.
6. Hanekom W.A., Hughes J., Mavinkurve M., Mendillo M., Watkins M., Gamieldien H., et al. Novel application of a whole blood intracellular cytokine detection assay to quantitate specific T-cell frequency in field studies. J Immunol Methods 2004, 291:185-195.
7. Sprangers M.C., Lakhai W., Koudstaal W., Verhoeven M., Koel B.F., Vogels R., et al. Quantifying adenovirus-neutralizing antibodies by luciferase transgene detection: addressing preexisting immunity to vaccine and gene therapy vectors. J Clin Microbiol 2003, 41:5046-5052.
8. Kagina B.M., Tameris M.D., Geldenhuys H., Hatherill M., Abel B., Hussey G.D., et al. The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8 T cell responses. Vaccine 2014, 32:5908-5917.
9. + T cells and their role in immunity. Crit Rev Immunol 2006, 26:317-352.
10. Barouch D.H., Kik S.V., Weverling G.J., Dilan R., King S.L., Maxfield L.F., et al. International seroepidemiology of adenovirus serotypes 5, 26, 35, and 48 in pediatric and adult populations. Vaccine 2011, 29:5203-5209.
11. Nwanegbo E., Vardas E., Gao W., Whittle H., Sun H., Rowe D., et al. Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States. Clin Diagn Lab Immunol 2004, 11:351-357.
12. Ouedraogo A., Tiono A.B., Kargougou D., Yaro J.B., Ouedraogo E., Kabore Y., et al. A phase 1b randomized, controlled, double-blinded dosage-escalation trial to evaluate the safety, reactogenicity and immunogenicity of an adenovirus type 35 based circumsporozoite malaria vaccine in Burkinabe healthy adults 18 to 45 years of age. PLoS ONE 2013, 8:e78679.
13. von Reyn C.F., Mtei L., Arbeit R.D., Waddell R., Cole B., Mackenzie T., et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010, 24:675-685.
14. Scriba T.J., Tameris M., Smit E., van der Merwe L., Hughes E.J., Kadira B., et al. A phase IIa trial of the new tuberculosis vaccine, MVA85A, in HIV- and/or Mycobacterium tuberculosis-infected adults. Am J Respir Crit Care Med 2012, 185:769-778.
15. Nell A.S., D'lom E., Bouic P., Sabate M., Bosser R., Picas J., et al. Safety, tolerability, and immunogenicity of the novel antituberculous vaccine RUTI: randomized, placebo-controlled phase II clinical trial in patients with latent tuberculosis infection. PLoS ONE 2014, 9:e89612.
16. Reither K., Katsoulis L., Beattie T., Gardiner N., Lenz N., Said K., et al. Safety and Immunogenicity of H1/IC31(R), an Adjuvanted TB Subunit Vaccine, in HIV-Infected Adults with CD4+ Lymphocyte Counts Greater than 350 cells/mm3: A Phase II, Multi-Centre, Double-Blind, Randomized, Placebo-Controlled Trial. PLoS ONE 2014, 9(12):e114602.
17. Mayosi B.M., Ntsekhe M., Bosch J., Pandie S., Jung H., Gumedze F., et al. Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. N Engl J Med 2014, 371:1121-1130.
18. Lahey T., Arbeit R.D., Bakari M., Horsburgh C.R., Matee M., Waddell R., et al. Immunogenicity of a protective whole cell mycobacterial vaccine in HIV-infected adults: a phase III study in Tanzania. Vaccine 2010, 28:7652-7658.
19. + T cells. Eur J Immunol 2010, 40:279-290.
20. +) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 2013, 31:2196-2206.